Cargando…

An appropriate choice for immunotherapy in malignant pleural mesothelioma

Detalles Bibliográficos
Autor principal:	Fujimoto, Nobukazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658483/ https://www.ncbi.nlm.nih.gov/pubmed/33181458 http://dx.doi.org/10.1016/j.ebiom.2020.103057

Ejemplares similares

Spare the lung: surgical treatment approach for malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2023)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021)

Physician requests by patients with malignant pleural mesothelioma in Japan
por: Nagamatsu, Yasuko, et al.
Publicado: (2019)

Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014)

Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma
por: Nakasuka, Takamasa, et al.
Publicado: (2015)

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
por: Tanaka, Takaaki, et al.
Publicado: (2022)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
por: Banerji, Shantanu, et al.
Publicado: (2021)

Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma
por: Pinton, Giulia, et al.
Publicado: (2017)

Refining classification of malignant pleural mesothelioma reveals its Achilles’ heel
por: Pateras, Ioannis S.
Publicado: (2019)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
por: Gray, Steven G.
Publicado: (2021)

Current status and progress in immunotherapy for malignant pleural mesothelioma
por: Sun, Boyang, et al.
Publicado: (2022)

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study
por: Nagamatsu, Yasuko, et al.
Publicado: (2018)

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
por: Bensaid, Douae, et al.
Publicado: (2018)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Treatment of malignant pleural effusions: the case for localized immunotherapy
por: Donnenberg, Albert D., et al.
Publicado: (2019)

Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
por: Offin, Michael, et al.
Publicado: (2022)

Phrenic Nerve Paralysis as the Initial Presentation in Pleural Sarcomatoid Mesothelioma
por: Makimoto, Go, et al.
Publicado: (2014)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma
por: Wheatley-Price, Paul, et al.
Publicado: (2022)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma
por: Treasure, Tom, et al.
Publicado: (2014)

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
por: Meirson, Tomer, et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?
por: Guo, Xiaotong, et al.
Publicado: (2023)

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
por: Kishimoto, Takumi, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_7k7s004tdmflfmj3i05u8hab4h